Vivani Announces Entry into Merger Agreement Between Wholly Owned Subsidiary Cortigent, Inc. and Nasdaq-listed ClearOne, Inc.

This is a long-term, high-risk merger with little current financial visibility for investors.

What the company is saying

The company is presenting a transformative merger between ClearOne, Inc. (NASDAQ:CLRO) and Cortigent, Inc., a subsidiary of Vivani Medical, Inc. (NASDAQ:VANI), positioning it as a strategic move to accelerate innovation and unlock future value. Management wants investors to believe this transaction will streamline operations, reduce Vivani’s direct expenditures on Cortigent, and enable a sharper focus on Vivani’s drug implant portfolio. The announcement claims that Vivani will receive 12,500,000 shares of ClearOne, resulting in Vivani owning a controlling 59.4% to 67.5% of the combined company, while ClearOne shareholders will be left with a much smaller 12.7% to 14.4% stake. The company emphasizes the planned $10–15 million capital raise, the Nasdaq relisting under a new ticker (“CRGT”), and the potential of the Orion artificial vision device, which is described as having completed a successful feasibility study with “promising” results. However, the announcement buries or omits any discussion of current revenues, profits, cash flows, or customer traction, and provides no hard data on clinical or commercial milestones. The tone is highly optimistic and forward-looking, with management projecting confidence in the transaction’s benefits and the future of the combined entity. Notable individuals named include Adam Mendelsohn, PhD (Vivani CEO), and Jonathan Adams (Cortigent CEO), both of whom are positioned as credible sector leaders, but there is no evidence of outside institutional investor participation or endorsement. The communication style is promotional, focusing on future potential rather than present fundamentals, and fits a classic biotech narrative of “platform plus pipeline” with a heavy reliance on anticipated milestones and capital infusions.

What the data suggests

The disclosed numbers are limited to the mechanics of the merger and the planned capital raise: Vivani will receive 12,500,000 shares of ClearOne, and post-transaction, Vivani is expected to own between 59.4% and 67.5% of the combined company, while legacy ClearOne shareholders will retain only 12.7% to 14.4%. The capital raise target is set at a minimum of $10 million and a maximum of $15 million, to be executed via a Form S-1 registration statement concurrent with the merger closing. There is no disclosure of revenue, net income, cash flow, or any operational metrics for any of the involved entities, making it impossible to assess financial trajectory, profitability, or even basic solvency. The only operational reference is to the Orion device’s feasibility studies, but no quantitative results, regulatory milestones, or commercialisation timelines are provided. There is no evidence that prior targets or guidance have been met, as none are disclosed. The financial disclosures are skeletal—sufficient to understand the share exchange and capital raise, but wholly inadequate for evaluating the underlying business health or growth prospects. An independent analyst would conclude that, based on the numbers alone, this is a high-dilution, capital-intensive transaction with no visibility into current or projected financial performance, and that the investment case rests entirely on future execution and unproven product development.

Analysis

The announcement is highly positive in tone, emphasizing the merger, planned capital raise, and future benefits such as accelerated development and Nasdaq listing. However, nearly all key claims are forward-looking, including the capital raise, closing timeline (Q3 2026), and product development milestones. The only realised facts are the signing of a definitive agreement and board approvals, but no operational, revenue, or profitability data is disclosed. The capital raise of $10–15 million is significant, but its benefits are long-dated and contingent on transaction closing and future development. The language inflates the signal by projecting substantial future benefits without supporting evidence of current financial or operational performance. The data supports only the transaction structure and intent, not realised value creation.

Risk flags

• ●Operational risk is high due to the lack of any disclosed revenue, profit, or cash flow figures for either ClearOne or Cortigent. Investors have no way to assess whether the combined entity is a going concern or a pre-revenue speculative venture.
• ●Financial risk is significant, as the transaction is predicated on raising $10–15 million in new capital via a Form S-1. If market conditions deteriorate or investor appetite wanes, the financing may fall short, jeopardizing the merger and future operations.
• ●Disclosure risk is acute: the announcement omits all key financial and operational metrics, providing no basis for evaluating business fundamentals or management’s ability to deliver on its promises.
• ●Pattern-based risk is evident in the heavy reliance on forward-looking statements and aspirational language, with 70% of claims being future-oriented and unsupported by current data. This is a classic red flag in speculative biotech and medtech deals.
• ●Timeline/execution risk is pronounced, as the transaction is not expected to close until Q3 2026, and all subsequent benefits are contingent on successful execution of multiple steps, including regulatory approvals, capital raise, and integration.
• ●Capital intensity is flagged: the need for at least $10 million in new funding underscores the cash burn and resource requirements of the business, with no evidence that these investments will yield near-term returns.
• ●Equity dilution risk is substantial: Vivani will control up to 67.5% of the combined company, leaving legacy ClearOne shareholders with a small minority stake. This raises questions about alignment and future dilution if further capital is needed.
• ●Leadership risk is moderate: while Adam Mendelsohn, PhD (Vivani CEO), and Jonathan Adams (Cortigent CEO) are named, there is no indication of outside institutional investor participation or validation, meaning the deal lacks third-party endorsement or oversight.

Bottom line

For investors, this announcement is a blueprint for a high-risk, long-dated merger and capital raise, not a signal of immediate value creation or operational progress. The narrative is built almost entirely on forward-looking statements, with no supporting evidence of current financial health, revenue generation, or commercial traction. The only hard numbers relate to share issuance, equity splits, and the size of the planned capital raise, all of which point to significant dilution and capital intensity. The involvement of sector CEOs is standard and does not constitute outside validation or institutional buy-in. To change this assessment, the company would need to disclose current or pro forma revenue, profitability, cash flow, and detailed clinical or regulatory milestones for its pipeline. In the next reporting period, investors should watch for actual capital raised, S-1 filing progress, regulatory updates on the Orion device, and—most importantly—any evidence of commercial or operational execution. At present, this announcement is not actionable for most investors; it is a signal to monitor, not to act on, unless one is comfortable with high-risk, speculative, pre-revenue biotech bets. The single most important takeaway is that this is a long-term, capital-intensive story with no current financial visibility—investors should demand much more data before committing capital.

Announcement summary

(NASDAQ:CLRO) ClearOne, Inc. will merge with Cortigent, Inc., a wholly owned subsidiary of Vivani Medical, Inc. (NASDAQ:VANI), in a transaction where Cortigent will become a wholly owned subsidiary of ClearOne. As consideration, Vivani will receive 12,500,000 shares of ClearOne common stock, and Vivani is anticipated to own 59.4% to 67.5% of the combined company, while former ClearOne shareholders will own 12.7% to 14.4%. ClearOne has agreed to file a registration statement on Form S-1 to raise a minimum of $10,000,000 and a maximum of $15,000,000 concurrently with the closing of the transaction. The transaction has been unanimously approved by the boards of directors of both Vivani and ClearOne and is expected to close in the third quarter of 2026, subject to customary closing conditions. Upon closing, ClearOne will be renamed “Cortigent Holdings, Inc.” (d/b/a Cortigent) and is expected to trade under Nasdaq ticker symbol “CRGT.” ThinkEquity acted as the sole financial advisor to Vivani for the transaction. The Orion artificial vision device completed a successful Early Feasibility Study last year and a 6-year early feasibility study in 2025 with promising tolerability and clinical activity results.

Disagree with this article?